Cancer drug prices cut by over 90 per cent: NPPA revises MRP of 543 brands, but Keytruda stays same

NPPA has cut maximum retail prices of 543 cancer drug brands, with some falling by over 90 per cent. Check out which medicines became cheaper and which prices remain unchanged.

New Delhi: The national drug price regulator has revised the maximum retail prices of 543 cancer drug brands in India, and for some of them the cut is more than 90 per cent. The National Pharmaceutical Pricing Control Authority (NPPA) released the updated list on Wednesday. Several generic and biosimilar brands have become far cheaper, including medicines used for breast cancer and for chemotherapy.

At the same time, costly originator drugs such as MSD Pharma’s immunotherapy Keytruda continue at their earlier prices. The new rates come into effect on November 9. Here is what the list shows: which drugs have seen the biggest drops and why campaigners say the relief is still limited.

Cancer drugs with the biggest........

© News9Live